Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:04 PM
Ignite Modification Date:
2025-12-24 @ 10:04 PM
NCT ID:
NCT03711435
Eligibility Criteria:
Inclusion Criteria:
* Case group inclusion criteria
1. According to the diagnostic criteria published in 2015, the New Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis, jointly developed by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Society;
2. aged 50 to 85 years old;
Control group inclusion criteria:
Health people match on the age (±3 years old) and gender with case group with 1:1 rate at the same time.
Exclusion Criteria:
* Case group exclusion criteria:
1. Those with severe heart, liver, kidney and other organ dysfunction or suffering from blood diseases;
2. with malignant tumors;
3. Severely infected people;
4. Pregnant and lactating women;
5. mental illness, serious obstacles and those who are unwilling to cooperate;
Control group exclusion criteria:
1. Those with severe heart, liver, kidney and other organ dysfunction or blood disease;
2. With malignant tumors;
3. Chest X-ray or chest low-dose CT suggesting intra-pulmonary interstitial fibrosis;
4. With chronic pulmonary diseases such as pulmonary interstitial disease, chronic obstructive pulmonary disease, and bronchial asthma;
5. With connective tissue disease and those with a history of exposure to occupational diseases;
6. Mental illness, serious obstacles and unwilling to cooperate.
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
50 Years
Maximum Age:
85 Years
Study:
NCT03711435
Study Brief:
Protocol Section:
NCT03711435